No Data
No Data
Zhejiang Garden Biopharmaceutical: Summary of Half-Year Report in 2024.
Zhejiang Garden Biopharmaceutical: Half-year report for the year 2024.
Zhejiang Garden BiopharmaceuticalLtd (SZSE:300401) Has A Somewhat Strained Balance Sheet
Zhejiang Garden Biopharmaceutical (300401.SZ): The price of the main raw material for Vitamin D3 production is currently fluctuating slightly.
On July 26, Gelunhui reported that an investor asked Zhejiang Garden Biopharmaceutical (300401.SZ) on the investor interaction platform, "Has the production material for vitamin D3 increased in price?" The company replied that the main production material for vitamin D3 has currently experienced only minimal price fluctuations.
Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Zhejiang Garden Biopharmaceutical (300401.SZ): The designed annual production capacity of the fodder-grade Vitamin D3 product of the company is 3600 tons.
Zhejiang Garden Biopharmaceutical (300401.SZ) stated on the investor interaction platform on June 27 that the design capacity of the company's fodder grade VD3 product is 3,600 tons per year. The core competitiveness of the company's vitamins sector mainly includes: a clear industry chain, leading production technology, lower production costs, prominent business scale and good market channel construction.
No Data